In diabetic rats, Noopept normalized basal blood glucose the day after streptozotocin administration.
In plain wordsIn rats with developing diabetes, Noopept normalized basal blood glucose compared with the abnormal glucose reported in active controls.
- Peptide
- Noopept (omberacetam)
- Outcome
- DecreaseBasal blood glucose after streptozotocin
- Study
ratn: not reported in source
Adult male Wistar rats with streptozotocin-induced developing diabetes- Comparator
- Active control
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 5 mg/kg · oral · Before each toxin injection and 16 days after the streptozotocin courseAs given in this study (rat).
Source sentences
Noopept normalized the basal blood glucose level and tolerance to glucose load on the next day after administration of streptozotocin.
3 context sentences(design, population, supporting numbers)
In active control group, spontaneously increase glucose level and reduced tolerance to glucose load (1000 mg/kg intraperitoneally) were observed on the next day after the third administration of toxin.
Developing diabetes was modeled on adult male Wistar rats by repeated intraperitoneal injections of streptozotocin in a subdiabetogenic dose of 30 mg/kg for 3 days.
Proline-containing dipeptide drug Noopept or a standard diabetic drug dipeptidyl peptidase-4 inhibitor sitagliptin was administered per os in a dose of 5 mg/kg before each injection of the toxin and then for 16 days after streptozotocin course.